228 related articles for article (PubMed ID: 31681336)
1. Mast Cells Are Mediators of Fibrosis and Effector Cell Recruitment in Dermal Chronic Graft-vs.-Host Disease.
Strattan E; Palaniyandi S; Kumari R; Du J; Hakim N; Huang T; Kesler MV; Jennings CD; Sturgill JL; Hildebrandt GC
Front Immunol; 2019; 10():2470. PubMed ID: 31681336
[TBL] [Abstract][Full Text] [Related]
2. Regulation of the functional activity of mast cells and fibroblasts by mononuclear cells in murine and human chronic graft-vs.-host disease.
Levi-Schaffer F; Segal V; Barak V; Rubinchik E; Nagler A
Exp Hematol; 1997 Mar; 25(3):238-45. PubMed ID: 9091300
[TBL] [Abstract][Full Text] [Related]
3. Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice.
Radojcic V; Paz K; Chung J; Du J; Perkey ET; Flynn R; Ivcevic S; Zaiken M; Friedman A; Yan M; Pletneva MA; Sarantopoulos S; Siebel CW; Blazar BR; Maillard I
Blood; 2018 Nov; 132(20):2188-2200. PubMed ID: 30181175
[TBL] [Abstract][Full Text] [Related]
4. Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia.
Jang JE; Kim SJ; Cheong JW; Hyun SY; Kim YD; Kim YR; Kim JS; Min YH
Ann Hematol; 2015 Feb; 94(2):275-82. PubMed ID: 25135450
[TBL] [Abstract][Full Text] [Related]
5. Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells.
Leveson-Gower DB; Sega EI; Kalesnikoff J; Florek M; Pan Y; Pierini A; Galli SJ; Negrin RS
Blood; 2013 Nov; 122(22):3659-65. PubMed ID: 24030387
[TBL] [Abstract][Full Text] [Related]
6. Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Tedder TF; Fujimoto M
Blood; 2013 Apr; 121(16):3274-83. PubMed ID: 23422748
[TBL] [Abstract][Full Text] [Related]
7. Mast Cell Involvement in Fibrosis in Chronic Graft-Versus-Host Disease.
Strattan E; Hildebrandt GC
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673565
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease.
Palaniyandi S; Strattan E; Kumari R; Mysinger M; Hakim N; Kesler MV; Apatira M; Bittencourt F; Wang L; Jia Z; Gururaja TL; Hill RJ; Hildebrandt GC
Bone Marrow Transplant; 2023 Aug; 58(8):924-935. PubMed ID: 37160943
[TBL] [Abstract][Full Text] [Related]
9. Ex Vivo CD34
Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
[TBL] [Abstract][Full Text] [Related]
10. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
[TBL] [Abstract][Full Text] [Related]
11. Naive and Stem Cell Memory T Cell Subset Recovery Reveals Opposing Reconstitution Patterns in CD4 and CD8 T Cells in Chronic Graft vs. Host Disease.
Soares MV; Azevedo RI; Ferreira IA; Bucar S; Ribeiro AC; Vieira A; Pereira PNG; Ribeiro RM; Ligeiro D; Alho AC; Soares AS; Camacho N; Martins C; Lourenço F; Moreno R; Ritz J; Lacerda JF
Front Immunol; 2019; 10():334. PubMed ID: 30894856
[TBL] [Abstract][Full Text] [Related]
12. CCL1 blockade alleviates human mesenchymal stem cell (hMSC)-induced pulmonary fibrosis in a murine sclerodermatous graft-versus-host disease (Scl-GVHD) model.
Lim JY; Ryu DB; Kim TW; Lee SE; Park G; Yoon HK; Min CK
Stem Cell Res Ther; 2020 Jun; 11(1):254. PubMed ID: 32586381
[TBL] [Abstract][Full Text] [Related]
13. Histamine release from mouse and rat mast cells cultured with supernatants from chronic murine graft-vs-host splenocytes.
Levi-Schaffer F; Mekori YA; Segal V; Claman HN
Cell Immunol; 1990 Apr; 127(1):146-58. PubMed ID: 1690607
[TBL] [Abstract][Full Text] [Related]
14. Extracellular vesicles derived from mesenchymal stem cells prevent skin fibrosis in the cGVHD mouse model by suppressing the activation of macrophages and B cells immune response.
Guo L; Lai P; Wang Y; Huang T; Chen X; Geng S; Huang X; Luo C; Wu S; Ling W; Huang L; Du X; Weng J
Int Immunopharmacol; 2020 Jul; 84():106541. PubMed ID: 32402950
[TBL] [Abstract][Full Text] [Related]
15. Effect of coculture of rodent mast cells with murine chronic graft-versus-host disease (cGVHD)-derived fibroblasts.
Levi-Schaffer F; Segal V; Baram D; Mekori YA
J Allergy Clin Immunol; 1992 Feb; 89(2):501-9. PubMed ID: 1371296
[TBL] [Abstract][Full Text] [Related]
16. Target antigens determine graft-versus-host disease phenotype.
Kaplan DH; Anderson BE; McNiff JM; Jain D; Shlomchik MJ; Shlomchik WD
J Immunol; 2004 Nov; 173(9):5467-75. PubMed ID: 15494494
[TBL] [Abstract][Full Text] [Related]
17. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
18. The proteome pattern cGvHD_MS14 allows early and accurate prediction of chronic GvHD after allogeneic stem cell transplantation.
Weissinger EM; Human C; Metzger J; Hambach L; Wolf D; Greinix HT; Dickinson AM; Mullen W; Jonigk D; Kuzmina Z; Kreipe H; Schweier P; Böhm O; Türüchanow I; Ihlenburg-Schwarz D; Raad J; Durban A; Schiemann M; Könecke C; Diedrich H; Holler E; Beutel G; Krauter J; Ganser A; Stadler M
Leukemia; 2017 Mar; 31(3):654-662. PubMed ID: 27677743
[TBL] [Abstract][Full Text] [Related]
19. Involvement of OX40 ligand+ mast cells in chronic GVHD after allogeneic hematopoietic stem cell transplantation.
Kotani A; Hori T; Fujita T; Kambe N; Matsumura Y; Ishikawa T; Miyachi Y; Nagai K; Tanaka Y; Uchiyama T
Bone Marrow Transplant; 2007 Mar; 39(6):373-5. PubMed ID: 17277792
[No Abstract] [Full Text] [Related]
20. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
